australian article

Tis gets a mention:


Tissue Therapies (TIS) 54.5c

HERE'S another episode of a heart-jerking reality series on unloved biotechs that would trade on higher valuations if they were properly understood.

In the case of Tissue Therapies, industry newsletter Bioshares notes last week's move by big pharma Shire to acquire Advanced BioHealing of the US for $US750m.

Advanced BioHealing markets Dermagraft, a bioengineered skin substitute used to treat diabetic foot ulcers. Tissue Therapies aims to commercialise VitroGro, which hasn't yet won regulatory approval but is for treating similar wounds. A European launch is expected early next year.

According to Bioshares, the Shire play "sends a clear signal that wound-healing technologies and products are now very appealing growth areas, which bodes well for Tissue therapies as it seeks to partner VitroGro over the next 12 months". After a $15m rights issue and placement, Tissue is valued at $84m.

http://www.theaustralian.com.au/business/opinion/battered-elders-sees-more-trouble-ahead/story-e6frg9lo-1226061486248